Evidence map›Paper›PMID 37645428›Full record

ArticleFrontiers in oncology2023

Brief report: risk stratification following curative therapy for stage I NSCLC.

Emily Butts, Denise Gococo-Benore, Tanmayi Pai, Muhamad Alhaj Moustafa, Fei Heng, Ruqin Chen, Yujie Zhao, Rami Manochakian, Yanyan Lou

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Healthcare professionals' perceived barriers and facilitators of risk-stratified follow-up care in lung cancer: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Patient-perceived barriers and facilitators for risk-stratified follow-up care in lung cancer: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emily ButtsDepartment of Internal Medicine, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Denise Gococo-BenoreDepartment of Internal Medicine, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Tanmayi PaiDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Muhamad Alhaj MoustafaDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Fei HengDepartment of Mathematics and Statistics, University of North Florida, Jacksonville, FL, United States.
Ruqin ChenDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Yujie ZhaoDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Rami ManochakianDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.
Yanyan LouDepartment of Hematology and Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Surveillance with computed tomography (CT) imaging following curative treatment of stage I non-small cell lung cancer (NSCLC) is important to identify recurrence or second primary lung cancers (SPLC). The pattern and risks of recurrence following curative therapy and optimal duration of surveillance scans remain unknown. The objective of our study is to assess the pattern of recurrence and development of SPLC to risk stratify patients with stage I NSCLC following curative therapy. Methods: We identified 261 patients who received curative therapy for stage I NSCLC at Mayo Clinic Florida. Data was collected on clinical and demographic features including gender, smoking history, stage, treatment, histologic subtype, and tumor grade. Kaplan-Meier method was used to evaluate the disease free survival (DFS). Cox proportional hazard model was used to identify risk factors for recurrence. Results: Negative tobacco history and stage IA tumors were associated with significantly prolonged DFS after adjusting for co-variates (p=0.001 and p=0.005). Univariate Cox proportional hazards model identified tobacco history and stage 1B as risk factors for recurrence with unadjusted hazard ratio (HR) of 2.8 and 2.0, respectively. After adjusting for covariates, only stage IB was statistically significant predictor of recurrence with a hazard ratio of 2.1 (Confidence Interval (CI) 95% 1.2-3.6; p=0.007). Conclusions: An individualized approach that considers risk factors of stage and smoking history may be useful in determining whether to continue annual CT surveillance after five years post curative therapy for stage I NSCLC.

Indexed as

imagingrecurrenceresectionsecond primary lung cancersurveillance

Identifiers

PMID37645428
PMCPMC10461311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.